Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients.

World journal of gastroenterology - 21 Feb 2012

Li Jian, Gong Ji-Fang, Li Jie, Gao Jing, Sun Nai-Ping, Shen Lin

Abstract excerpt

AIM: To investigate the efficacy and safety of imatinib dose escalation in Chinese patients with advanced gastrointestinal stromal tumor (GIST). METHODS: Advanced GIST patients previously failing 400 mg imatinib treatment were enrolled in this study. Patients received imatinib with dose escalation to 600 mg/d, and further dose escalation to 800 mg/d if imatinib 600 mg/d failed. Progression-free survival, overall...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Disease-Free Survival
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Share to Receptor, Platelet-Derived Growth Factor alpha

Source

Open in PubMed Open full text

Identifiers

PMID: 22363143
DOI: 10.3748/wjg.v18.i7.698
PMCID: PMC3281229

Genes

PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients.PMID 22363143Read ↗

Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.Semantic proximity Read ↗

The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor.Semantic proximity Read ↗

Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials.Semantic proximity Read ↗

Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.Semantic proximity Read ↗

A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.Semantic proximity Read ↗

Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study.Semantic proximity Read ↗

Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients.Semantic proximity Read ↗

[Clinical analysis of imatinib in patients with advanced gastrointestinal stromal tumor].Semantic proximity Read ↗

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.Semantic proximity Read ↗

Personalized Dose of Adjuvant Imatinib in Patients with Gastrointestinal Stromal Tumors: Results from a Population Pharmacokinetic Analysis.Semantic proximity Read ↗

Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?Semantic proximity Read ↗

Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.